Search Result

Results for "

MiaPaCa-2

" in MedChemExpress (MCE) Product Catalog:

標的別:	Adenosine Receptor (1) Akt (1) Apoptosis (16) Atg8/LC3 (1) ATM/ATR (1) Aurora Kinase (1) Autophagy (1) Bacterial (1) Bcl-2 Family (2) Biochemical Assay Reagents (1) c-Met/HGFR (2) Caspase (2) CDK (1) Cyclophilin (1) Cytochrome P450 (1) Drug Derivative (2) ERK (2) Farnesyl Transferase (2) HDAC (1) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (3) Histone Methyltransferase (1) IAP (1) Interleukin Related (3) IRAK (1) MDM-2/p53 (3) Mps1 (1) mTOR (1) Na+/K+ ATPase (1) p38 MAPK (1) PARP (1) PDGFR (2) PERK (2) PI3K (3) Pim (1) Proton Pump (1) RAR/RXR (1) Ras (9) Reactive Oxygen Species (ROS) (2) Reference Standards (2) ROCK (1) SOS1 (1) Src (1) TNF Receptor (3) Trk Receptor (2) VDAC (1)
研究分野別:	Cancer (42) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (4)
クリックケミストリー:	Azide (1)
Oligonucleotides:	Aptamers (1)

阻害剤およびアゴニスト

ペプチド

阻害性抗体

クリックケミストリー

オリゴヌクレオチド

製品番号	製品名	Target	研究分野	構造式

HY-B0113

Omeprazole Maximum Cited Publications 8 Publications Verification H 16868	Na+/K+ ATPase Proton Pump Bacterial Cytochrome P450 Apoptosis Autophagy Atg8/LC3 TNF Receptor Interleukin Related	Infection Neurological Disease Inflammation/Immunology Cancer
Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits *CYP2C19, CYP3A4, and CYP2C9* activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects ^[2] .

HY-P99221

Tanezumab RN-624; PF 4383119	Trk Receptor	Neurological Disease Inflammation/Immunology Cancer
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia ^[2].

HY-W011404

Tributyrin 1 Publications Verification Glyceryl tributyrate	Apoptosis TNF Receptor Interleukin Related	Metabolic Disease Cancer
Tributyrin (Glyceryl tributyrate), a neutral short-chain fatty acid triglyceride, is a stable and rapidly absorbed proagent of Butyric Acid. Tributyrin diffuses through biological membranes and is metabolized by intracellular lipases, releasing effective butyrate directly into the cell in vivo. Tributyrin has potent antiproliferative, proapoptotic and differentiation-inducing effects .

HY-162431

Calderasib MK-1084	Ras	Cancer
Calderasib (MK-1084) is a selective KRAS G12C inhibitor. Calderasib exhibits anticancer activity and can be used either alone or in combination with Pembrolizumab (HY-P9902) for cancer research .

HY-160023

Elisrasib D3S-001	Ras PERK	Cancer
Elisrasib (D3S-001) is an orally active and selective inhibitor for KRAS. Elisrasib inhibits the proliferation of KRAS ^G12C mutant H358 and MIA-PA-CA-2. D3S-001 also inhibits the phosphorylation of cellular *ERK1/2*. Elisrasib exhibits good metabolic stability in hepatocytes, liver microsomes, plasma and whole blood in various species. D3S-001 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice .

HY-P3509

PNC-28	MDM-2/p53	Cancer
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research ^[2].

HY-115903

HIF-1α-IN-2 4 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies (IC₅₀s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 suppresses HIF-1α expression by blocking transcription and protein translation .

HY-14653

Amsilarotene TAC-101; Am 555S	RAR/RXR Apoptosis	Cancer
Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with K_i of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer ^[2] .

HY-P3509A

PNC-28 acetate	MDM-2/p53	Cancer
PNC-28 acetate is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 acetate can be used for pancreatic cancer research ^[2].

HY-115903A

HIF-1α-IN-2 hydrochloride 4 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1α-IN-2 hydrochloride is an effective HIF-1α inhibitor with anticancer potencies (IC₅₀s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 hydrochloride suppresses HIF-1α expression by blocking transcription and protein translation .

HY-W016582

Methyl 2-(bromomethyl)acrylate	Biochemical Assay Reagents	Cancer
Methyl 2-(bromomethyl)acrylate is a biochemical Assay Reagents .Methyl 2-(bromomethyl)acrylate inhibits cell proliferation in breast cancer and pancreatic cancer cells. Methyl 2-(bromomethyl)acrylate can be used for the research of breast cancer and pancreatic cancer .

HY-119257

ABT-100 1 Publications Verification	Farnesyl Transferase Apoptosis	Cancer
ABT-100, a chemical probe, is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC₅₀s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity .

HY-16232

Glufosfamide D 19575; Glucosylifosfamide mustard	Apoptosis Caspase Bcl-2 Family	Cancer
Glufosfamide is a glucose-conjugated alkylating cytotoxic agent and a derivative of Ifosfamide (HY-17419). Glufosfamide induces apoptosis frequency and increase the expression of caspase-9 and caspase-3 in cancer cells. Glufosfamide shows great anti-tumor activity in MiaPaCa-2-RFP mouse model. Glufosfamide can be used for the study of hepatocellular carcinoma, prostate cancer and pancreatic carcinoma ^[2] .

HY-12862

Mps1-IN-7	Mps1	Cancer
Mps1-IN-7 is a potent MPS1 inhibitor (IC₅₀ of 0.020 μM) over JNK1 and JNK2 (JNK1 IC₅₀= 0.11 μM, JNK2 IC₅₀=0.22 μM). Mps1-IN-7 inhibit SW620, CAL51, Miapaca-2, RMG1 cell growth with GI₅₀ values of 0.065, 0.068, 0.25, and 0.110 μM,respectively .

HY-174243

KRASG12D-IN-5	Ras	Cancer
KRASG12D-IN-5 (Compound 241) is an orally active KRAS(G12D) inhibitor with an IC₅₀ of 11 nM. KRASG12D-IN-5 has potent anticancer activity with no significant cytotoxicity against BxPC-3 (WT), KRAS mutation AsPC-1 (G12D) and MIAPaCa-2 cells (G12C) with CC₅₀s of 10.37, 0.76 and 0.3 μM, respectively. KRASG12D-IN-5 can be used for cancer research, such as lung, pancreatic and colorectal cancer .

HY-117893

BIM-46068	Farnesyl Transferase Ras	Cancer
BIM-46068 is a potent, selectively human brain Farnesyltransferase (FTase) inhibitor (IC₅₀ = 91.4 nM). BIM-46068 can specifically inhibit Ras processing in MiaPaCa-2 cancer cells. BIM-46068 can be used for the study of pancreatic cancer .

HY-149511

MET/PDGFRA-IN-2	c-Met/HGFR Apoptosis PDGFR	Cancer
MET/PDGFRA-IN-2 (compound 8h) is a MET and PDGFRA protein inhibitor. MET/PDGFRA-IN-2 induces cell apoptosis. MET/PDGFRA-IN-2 inhibits proliferation of MET-positive cells (IC₅₀s: 9.7, 6.1, 12.0, 11.5, 8.6, 34.4 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively) .

HY-149510

MET/PDGFRA-IN-1	c-Met/HGFR Apoptosis PDGFR	Cancer
MET/PDGFRA-IN-1 (compound 8c) is a MET and PDGFRA protein inhibitor (IC₅₀: 36 μM for MET). MET/PDGFRA-IN-1 inhibits MET phosphorylation and induces cell apoptosis. MET/PDGFRA-IN-1 inhibits proliferation of MET-positive cells (IC₅₀s: 15.3, 19.0, 22.0, 25.6, 21.0, 31.5 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively) .

HY-153400

ATR-IN-22	ATM/ATR	Cancer
ATR-IN-22 (Compound 34) is an orally active ATR inhibitor. ATR-IN-22 inhibits MIAPaCa-2 proliferation (IC₅₀ <1 μM). ATR-IN-22 shows anti-tumor activity in colon cancer .

HY-176231

PRMT5-IN-51	Histone Methyltransferase	Cancer
PRMT5-IN-51 (compound 16–19F) is a potent PRMT5 inhibitor. PRMT5-IN-51 shows antiproliferative activity .

HY-147767

PI3Kα-IN-6	PI3K Apoptosis Reactive Oxygen Species (ROS)	Cancer
PI3Kα-IN-6 (Compound 5b) is a PI3Kα inhibitor. PI3Kα-IN-6 exhibits anticancer potential and no toxicity in normal cells. PI3Kα-IN-6 increases generation of ROS, reduces mitochondrial membrane potential (MMP) and induces apoptosis .

HY-164186

M9-5 sodium	Cyclophilin	Others
M9-5 sodium is an aptamer targeting cyclophilin B. M9-5 binds to the MiaPaCa-2 secretory protein with high affinity and can be used as a blood biomarker for the detection of pancreatic cancer.

HY-161858

EpskA21	PI3K Akt Apoptosis	Cancer
EpskA21 is an inhibitor for PI3K/AKT signaling pathway, and inhibits the proliferation of cancer cells MCF-7, A549, MIA-PaCa-2, Panc-1 and HepG2, with IC₅₀ of 1.3-7.24 μM. EpskA21 inhibits the cell migration, arrests the cell cycle at G2/M (MCF-7) and S (MIA-PaCa-2) phase, and induces apoptosis in MCF-7 and MIA-PaCa-2. EpskA21 causes the mitochondrial dysfunction .

HY-W011404R

Tributyrin (Standard) Glyceryl tributyrate (Standard)	Apoptosis Reference Standards TNF Receptor Interleukin Related	Metabolic Disease Cancer
Tributyrin (Glyceryl tributyrate), a neutral short-chain fatty acid triglyceride, is a stable and rapidly absorbed proagent of Butyric Acid. Tributyrin diffuses through biological membranes and is metabolized by intracellular lipases, releasing effective butyrate directly into the cell in vivo. Tributyrin has potent antiproliferative, proapoptotic and differentiation-inducing effects .

HY-170550

KRAS G12C inhibitor 69	Ras ERK	Cancer
KRAS G12C inhibitor 69 (Compound K09) is the inhibitor for mutant RAS protein KRASG12C with an IC₅₀ of 4.36 nM. KRAS G12C inhibitor 69 inhibits the ERK phosphorylation in NCI-H358 and MIA-PACA-2 with an IC₅₀ of 12 nM and 7 nM. KRAS G12C inhibitor 69 inhibits the proliferation of cancer cell NCI-H358 and MIA-PACA-2 with IC₅₀ of 3.15 nM and 2.33 nM .

HY-149635

HIF-1α-IN-6	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1α-IN-6 (compound 3s) is a HIF-1α inhibitor with IC₅₀ values of 0.6 and 53.3 nM observed in MiaPaCa-2 and MDA-MB-231 cells. HIF-1α-IN-6 can inhibit HIF-1α expression by decreasing the level of HIF-1α mRNA .

HY-170958

Scr-IN-1	Src Apoptosis	Cancer
Scr-IN-1 (Compound 4e) is a Tyrosine kinase inhibitor. Scr-IN-1 inhibits HCT-116 cells and MIA-PaCa-2 cells with IC₅₀s of 0.16 μM and 1.16 μM, respectively. Scr-IN-1 displays selectivity profile on HCT-116 cells and MIA-PaCa-2 cells with SI > 625 and SI > 86, respectively. Scr-IN-1 induces Apoptosis in HCT-116 colon cancer cell and does not cause any change in the rate of necrotic cells. Scr-IN-1 is a novel SRC kinase inhibitor candidate for HCT-116 cells. Scr-IN-1 is potential for cancer research .

HY-145900

S100A2-p53-IN-1	MDM-2/p53	Cancer
S100A2-p53-IN-1 (compound 51) is a *S100A2-p53* interactions inhibitor. S100A2 is a Ca ²⁺ binding protein with implications in cell signaling and is known to be upregulated in pancreatic cancer. S100A2-p53-IN-1 can inhibit the growth of the MiaPaCa-2 pancreatic cancer cell line (GI ⁵⁰ of 1.2-3.4 μM) .

HY-159511

Hedgehog IN-7	Hedgehog	Cancer
Hedgehog IN-7 (Compound 8g), a purine derivative, acts as an inhibitor of Hedgehog, capable of reducing the expression of Hedgehog genes and inhibiting Hedgehog signaling. Hedgehog IN-7 has significant cytotoxicity and selectivity towards the Hedgehog pathway-dependent pancreatic cancer cell Mia-PaCa-2 cells and can be used in the research of pancreatic cancer .

HY-169830

2-(Cyclohexylmethyl)-plumbagin	Drug Derivative Apoptosis	Cancer
2-(Cyclohexylmethyl)-plumbagin is a derivative of the naphthoquinone compound Plumbagin (HY-N1497). Under nutrient-deprived conditions, 2-(Cyclohexylmethyl)-plumbagin selectively exhibits cytotoxicity against PANC-1 human pancreatic cancer cells (PC₅₀ = 0.11 µM) and reduces the phosphorylation of Akt and mTOR in PANC-1 cells. 2-(Cyclohexylmethyl)-plumbagin also induces apoptosis (Apoptosis) in PANC-1 cells at a concentration of 1 µM. Additionally, 2-(Cyclohexylmethyl)-plumbagin reduces tumor volume and weight in a xenograft MiaPaCa-2 pancreatic cancer mouse model .

HY-170527

Anticancer agent 260	Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Cancer
Anticancer agent 260 (Compound 3g/4d) is an orally active anticancer agent, that inhibits the proliferation of cancer cell HCT-116, MIA-PaCa2 and MDA-MB231 with IC₅₀s of 98.7, 81.0, and 77.2 µg/mL, respectively. Anticancer agent 260 exhibits promotes ulcer formation and lipid peroxidation, anti-inflammatory and analgesic efficacy ^[2].

HY-168716

SOS1-IN-17	SOS1 Ras	Cancer
SOS1-IN-17 (Compound 8d) is an orally active inhibitor for SOS1-KRASG12C interaction with an IC₅₀ of 5.1 nM. SOS1-IN-17 inhibits ERK phosphorylation in DLD-1 cell with an IC₅₀ of 18 nM. SOS1-IN-17 exhibits anti-proliferative activity in KRASG12C mutated Mia-Paca-2 cell with an IC₅₀ of 0.11 μM. SOS1-IN-17 exhibits antitumor efficacy against pancreatic cancer in mouse model .

HY-186024

KRAS-IN-51	Ras ERK	Cancer
KRAS-IN-51 (Compound 597a) is a KRas G12V inhibitor, with its IC₅₀ for KRas G12V being 2.9 nM; K_D values are 17 (at 20°C) and 68 (at 37°C) nM. KRAS-IN-51 inhibits the phosphorylation of pERK. KRAS-IN-51 has anti-proliferative activity against SW620 and MIAPaCa-2. KRAS-IN-51 can be used for research on colorectal cancer and pancreatic cancer .

HY-115862

Benzo[c][1,8]naphthyridin-6(5H)-one	Adenosine Receptor PARP Aurora Kinase	Cardiovascular Disease Cancer
Benzo[c][1,8]naphthyridin-6(5H)-one exhibits low micromolar affinity to human adenosine receptor (AR) A₁ and hA_2A, with K_i of 4.6 and 4.8 μM. Benzo[c][1,8]naphthyridin-6(5H)-one is inhibitor for poly ADP-ribose polymerase-1 (PARP-1) and aurora kinase A, with IC₅₀ of 0.311 and 5.5 μM ^[2] .

HY-120561

PC-046	Trk Receptor IRAK Pim Apoptosis	Cancer
PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC₅₀ of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC₅₀ of 7.5-130 nM. PC-046 induces apoptosis and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice .

HY-168919

KRASG12C IN-16	Ras Apoptosis p38 MAPK PI3K mTOR	Cancer
KRASG12C IN-16 (Compound SK-17) is a selective, covalent and an orally active KRAS ^G12C inhibitor. KRASG12C IN-16 induces Apoptosis. KRASG12C IN-16 effectively prevents the activation of MAPK and PI3K/mTOR signaling pathways. KRASG12C IN-16 displays anti-tumor activity against pancreatic cancer .

HY-132979

KRAS G12C inhibitor 18	Ras	Cancer
KRAS G12C inhibitor 18 is a potent and orally active KRAS G12C inhibitor. Anti-tumor activities .

HY-151375

CDK9/10/GSK3β-IN-1	CDK	Cancer
CDK9/10/GSK3β-IN-1 (compound 13c) is a kinase inhibitor (Flavopiridol (HY-10005) analogue) that effectively inhibits HsGSK3β (IC₅₀=59 nM), HsCDK9/CyclinT (IC₅₀=64 nM), HsCDK5/p25 (IC₅₀=1.093 μM) and *HsCDK2/CyclinA* (IC₅₀=1.725 μM). CDK9/10/GSK3β-IN-1 has anti-cancer cellular activity comparable to or higher than that of Flavopiridol. CDK9/10/GSK3β-IN-1 shows high anti-proliferative activity in vitro against up to seven cancer cell lines .

HY-172748

9β-Hydroxyhexahydrocannabinol	Drug Derivative	Neurological Disease Cancer
9β-Hydroxyhexahydrocannabinol is a synthetic cannabinoid derivative. 9β-Hydroxyhexahydrocannabinol exhibits cytotoxicity against various tumor cell lines, such as HCT-116, MCF-7, K562, MIAPaCa-2, PANC-1, A549, PC-3 and SW-620, with IC₅₀ values ranging from 15.23 to 33.74 μM. 9β-Hydroxyhexahydrocannabinol can be used in the study of cancer .

HY-158076

S2/IAPinh	IAP	Cancer
S2/IAPinh is a conjugate, which consist of an inhibitor for the apoptosis protein inhibitor (IAPinh) and a ligand for sigma 2 SW43. S2/IAPinh exhibits an anti-proliferative and apoptotic-inducing effect through degradation of the cellular inhibitor for apoptosis protein (clAP-1) .

HY-172177

ROCK/HDAC-IN-2	Apoptosis HDAC ROCK	Cancer
ROCK/HDAC-IN-2 (Compound C-9) is a ROCK/HDAC inhibitor, with IC₅₀ values of 0.185 µM, 0.8 µM, and 0.7 µM for HDAC6, ROCK1, and *ROCK2, respectively. ROCK/HDAC-IN-2 can induce apoptosis* and changes in mitochondrial membrane potential in cancer cells, demonstrating significant antitumor activity. ROCK/HDAC-IN-2 can be used in the research of pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) .

HY-16232R

Glufosfamide (Standard) D 19575 (Standard); Glucosylifosfamide mustard (Standard)	Reference Standards Apoptosis Bcl-2 Family Caspase	Cancer
Glufosfamide (Standard) is the analytical standard of Glufosfamide. This product is intended for research and analytical applications. Glufosfamide is a glucose-conjugated alkylating cytotoxic agent and a derivative of Ifosfamide (HY-17419). Glufosfamide induces apoptosis frequency and increase the expression of caspase-9 and caspase-3 in cancer cells. Glufosfamide shows great anti-tumor activity in MiaPaCa-2-RFP mouse model. Glufosfamide can be used for the study of hepatocellular carcinoma, prostate cancer and pancreatic carcinoma ^[2] .

HY-181529

NCATS-SM0225	VDAC PERK	Cancer
NCATS-SM0225 is an endoplasmic reticulum-associated degradation (ERAD) inhibitor and a direct binder of VDAC1, *VDAC2* and VDAC3. NCATS-SM0225 exhibits an IC₅₀of 1.02 μM for ERAD and a K_d of 3.13 μM for human VDAC1 binding. NCATS-SM0225 disrupts cellular calcium homeostasis, enhances VDAC1-IP3R coupling and activating PERK. NCATS-SM0225 selectively kills cancer cells, exhibits tumor growth inhibitory effects in melanoma xenograft models. NCATS-SM0225 can be used for research on multiple cancers including melanoma, as well as the molecular mechanisms of ERAD and calcium homeostasis regulation .

製品番号	製品名	Target	研究分野

HY-P3509

PNC-28	MDM-2/p53	Cancer
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research ^[2].

HY-P3509A

PNC-28 acetate	MDM-2/p53	Cancer
PNC-28 acetate is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 acetate can be used for pancreatic cancer research ^[2].

製品番号	製品名	Target	研究分野	Image

HY-P99221

Tanezumab RN-624; PF 4383119	Trk Receptor	Neurological Disease Inflammation/Immunology Cancer
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia ^[2].

製品番号	製品名		Classification

HY-159511

Hedgehog IN-7		Azide
Hedgehog IN-7 (Compound 8g), a purine derivative, acts as an inhibitor of Hedgehog, capable of reducing the expression of Hedgehog genes and inhibiting Hedgehog signaling. Hedgehog IN-7 has significant cytotoxicity and selectivity towards the Hedgehog pathway-dependent pancreatic cancer cell Mia-PaCa-2 cells and can be used in the research of pancreatic cancer .

製品番号	製品名		Classification

HY-164186

M9-5 sodium		Aptamers
M9-5 sodium is an aptamer targeting cyclophilin B. M9-5 binds to the MiaPaCa-2 secretory protein with high affinity and can be used as a blood biomarker for the detection of pancreatic cancer.

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: